… crizotinib can deliver prolonged freedom from lung cancer progression with modest toxicity,
they do not appear to cure advanced NSCLC even in patients … to resistance to crizotinib have …

… might also be active in crizotinib-resistant patients harboring ALK mutations … patients can
continue taking crizotinib beyond progression as shown in the phase I study. However, patients …

… trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic
ALK-positive lung cancer who had received one prior platinum-based regimen. Patients …

… lung cancer population within this study, crizotinib showed marked efficacy, with tumour
shrinkage in over 90% of patients … as the number of patients assessed has increased over time, …

… comparing crizotinib with chemotherapy in 343 patients with … Patients were randomly assigned
to receive oral crizotinib at a … Crossover to crizotinib treatment after disease progression …

… (TKI) crizotinib showed marked antitumour activity in patients with … whether crizotinib affects
overall survival in these patients, … in crizotinib-treated patients in the trial and crizotinib-naive …

… in a category, 19 additional patients are to be enrolled. This study is part of an ongoing
phase 1 crizotinib study (NCT00585195). Patients received crizotinib 250 mg BID. Responses …

… had a high response rate to crizotinib in a prior … crizotinib 250 mg BID continuously in 3-week
cycles. Disease response was evaluated by RECIST 1.1 every 6 weeks and safety/patient-…

… in lung cancer is ∼ 6000 patients/year in … crizotinib 250 mg BID is sufficient to achieve
>75% ALK inhibition in tumors. In conclusion, steady-state concentrations of crizotinib in patients …

… Phase I and II studies of crizotinib in ALK-positive lung cancer have demonstrated significant
activity and impressive clinical benefit, which led to its early approval by USFDA in 2011. …